Diagnostics and treatment of bronchiectasis;Diagnostiek en behandeling van bronchiëctasieën

Nederlands Tijdschrift voor Geneeskunde

Volumn 148, Issue 3, 2004, Pages 120-125

  Van Haren, E H J ^a,b   Mannes, G P M ^a  

^a Sittard Geleen Heerlen   (Netherlands)

^b TWENTEBORG HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; COLISTIN; CORTICOSTEROID; MACROLIDE; TOBRAMYCIN;

ANTIBIOTIC THERAPY; ARTIFICIAL EMBOLISM; BACTERIAL INFECTION; BRONCHIECTASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CYSTIC FIBROSIS; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; DISEASE EXACERBATION; HEMOPTYSIS; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; LUNG RESECTION; PSEUDOMONAS; RESPIRATORY TRACT INFECTION; REVIEW; THORAX;

ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; BRONCHIECTASIS; HUMANS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0347764513     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. O'Brien C, Guest PJ, Hill SL, Stockley RA. Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care. Thorax 2000;55:635-42.
2. Nicotra MB, Rivera M, Dale AM, Shepherd F, Carter R. Clinical. pathophysiologic, and microbiologic characterization of bronchiectasis in an aging cohort. Chest 1995;108:955-61.
3. Pasteur MC, Helliwell SM, Houghton SJ, Webb SC, Foweraker JE, Coulden RA, et al. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med 2000;162(4 Pt 1): 1277-84.
4. Ho PL, Chan KN, Ip MSM, Lam WK, Ho CS, Yuen KY, et al. The effect of Pseudomonas aeruginosa infection on clinical parameters in steady-state bronchiectasis. Chest 1998;114:1594-8.
5. Evans SA, Turner SM, Bosch BJ, Hardy CC, Woodhead MA. Lung function in bronchiectasis. Eur Respir J 1996;9:1601-4.
6. Bruggen-Bogaarts BAHA van der, Bruggen HMJG van der, Waes PFGM van, Lammers JWJ. Screening for bronchiectasis. Chest 1996;109:608-11.
7. Tsang KW, Chan KN, Ho PL, Zheng L, Ooi GC, Ho JCM, et al. Sputum elastase in steady-state bronchiectasis. Chest 2000;117:420-6.
8. Angrill J, Agusti C, de Celis R, Filella X, Rano A, Elena M, et al. Bronchial inflammation and colonization in patients with clinically stable bronchiectasis. Am J Respir Crit Care Med 2001;164:1628-32.
9. Schaaf B, Wieghorst A, Aries SP, Dalhoff K, Braun J. Neutrophil inflammation and activation in bronchiectasis. Respiration 2000;67:52-9.
10. Sheikh A, Nolan D, Greenstone M. Long-acting beta-2-agonists for bronchiectasis [Cochrane review]. The Cochrane Library. Issue 4. Oxford: Update Software: 2001.
11. Lasserson T, Holt K, Evans D, Greenstone M. Anticholinergic therapy for bronchiectasis [Cochrane review]. The Cochrane Library. Issue 4. Oxford: Update Software; 2001.
12. O'Donnell AE, Barker AF, Ilowite JS, Fick RB. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. Chest 1998;113:1329-34.
13. Thompson CS, Harrison S, Ashley J, Day K, Smith DL. Randomised crossover study of the Flutter device and the active cycle of breathing technique in non-cystic fibrosis bronchiectasis. Thorax 2002;57:446-8.
14. Jones A, Rowe BH. Bronchopulmonary hygiene physical therapy in bronchiectasis and chronic obstructive pulmonary disease: a systematic review. Heart Lung 2000;29:125-35.
15. Wills P, Greenstone M. Inhaled hyperosmolar agents for bronchiectasis [Cochrane review]. The Cochrane Library. Issue 1. Oxford: Update Software; 2002.
16. Crockett AJ, Cranston JM, Latimer KM, Alpers JH. Mucolytics for bronchiectasis [Cochrane review]. The Cochrane Library. Issue I. Oxford: Update Software; 2001.
17. Cozijnsen M, Gans SJM, Bruggen-Boogaarts BA van der, Lammers JWJ. Bronchiëctasieën; kliniek, diagnostiek en behandeling. Ned Tijdschr Geneeskd 1994;138:148-52.
18. Agasthian T, Deschamps C, Trastek VF, Allen MS, Pairolero PC. Surgical management of bronchiectasis. Ann Thorac Surg 1996;62:976-80.
19. Corless JA, Warburton CJ. Surgery vs non-surgical treatment for bronchiectasis [Cochrane review]. The Cochrane Library. Issue 4. Oxford: Update Software; 2000.
20. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999:340:23-30.
21. Moss RB. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest 2002:121:55-63.
22. Barker AF, Couch L, Fiel SB, Gotfried MH, Ilowite J, Meyer KC, et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med 2000;162(2 Pt 1):481-5.
23. Loukides S, Horvath I, Wodehouse T, Cole PJ, Barnes PJ. Elevated levels of expired breath hydrogen peroxide in bronchiectasis. Am J Respir Crit Care Med 1998:158:991-4.
24. Tsang KWT, Ho PL, Lam WK, Ip MSM, Chan KN, Ho CS, et al. Inhaled fluticasone reduces sputum inflammatory indices in severe bronchiectasis. Am J Respir Crit Care Med 1998;158:723-7.
25. Kolbe J, Wells A, Ram FS. Inhaled steroids for bronchiectasis [Cochrane review]. The Cochrane Library. Issue 2. Oxford: Update Software; 2000.
26. Lasserson T, Holt K, Greenstone M. Oral steroids for bronchiectasis (stable and acute exacerbations) [Cochrane review]. The Cochrane Library. Issue 4. Oxford: Update Software; 2001.
27. Nagai H, Shishido H, Yoneda R, Yamaguchi E, Tamura A, Kurashima A. Long-term low-dose administration of erythromycin to patients with diffuse panbronchiolitis. Respiration 1991:58:145-9.
28. Tsang KWT, Ho PI, Chan KN, Ip MSM, Lam WK, Ho CS, et al. A pilot study of low-dose erythromycin in bronchiectasis. Eur Respir J 1999;13:361-4.
29. Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 2002;57:212-6.
30. Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 2002;360:978-84.
31. Jaffé A, Bush A. Anti-inflammatory effects of macrolides in lung disease. Pediatr Pulmonol 2001;31:464-73.
32. Tagaya E, Tamaoki J, Kondo M, Nagai A. Effect of a short course of clarithromycin therapy on sputum production in patients with chronic airway hypersecretion. Chest 2002;122:213-8.
33. Kobayashi H. Biofilm disease: its clinical manifestation and therapeutic possibilities of macrolides. Am J Med 1995;99:26S-30S.
34. Tsang KW, Ng P, Ho PL, Chan S, Tipoe G, Leung P, et al. Effects of erythromycin on Pseudomonas aeruginosa adherence to collagen and morphology in vitro. Eur Respir J 2003;21:402-6.